More than 60 years of clinical experience

More than 60 years of clinical experience Glucophage® (metformin) was first used in clinical practice over 60 years ago 1. Extensive data nowadays support its use as first-line treatment in patients with type 2 diabetes 2.2,3,4 In 1959, two years after the first clinical study, Glucofag® was first authorized on the market in France. In 2017, Glucophage (metformin) celebrated the 60th anniversary of its first clinical use and its continued position as a cornerstone in the treatment of type 2 diabetes.

  1. NICE guideline ph38: Type 2 diabetes: prevention in people at high risk. Published 12 July 2012. Available at: https://www.nice.org.uk/guidance/ph38/chapter/8-glossary#pre-diabetes. Last accessed March 2018.
  2. ADA (American Diabetes Association). Standards of Medical Care in Diabetes. Diabetes Care. 2013;36(1):S11 66.
  3. IDF (International Diabetes Federation). (2012). Clinical Guidelines Task Force: Global guideline for the management of type 2 diabetes. Available at: https://www.idf.org/e-library/guidelines/79-global-guideline-for-type-2-diabetes Last accessed March 2018.
  4. DPP Research Group. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. N Engl J Med. 2002;346:393 403.
  5. ESC (European Society of Cardiology). Diabetes, Prediabetes and Cardiovascular Diseases with the EASD. Available at: https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Diabetes-Pre-Diabetes-and-Cardiovascular-Diseases-developed-with-the-EASD. Last accessed November 2017
  6. SMC. UK 2017. Glucophage SR 500mg, 750mg and 1000mg prolonged release tablets.